PAXLOVID (nirmatrelvir/ritonavir)
- COVID-19
150 mg-100 mg tablets in a dose pack (Renal Dose)
- by oral route 2 times per day per package directions for 5 days
300 mg (150 mg x 2)-100 mg tablets in a dose pack
- by oral route 2 times per day per package directions for 5 days
Paxlovid 150 mg-100 mg tablets in a dose pack (Renal Dose)
- by oral route 2 times per day per package directions for 5 days
Paxlovid 300 mg (150 mg x 2)-100 mg tablets in a dose pack
- by oral route 2 times per day per package directions for 5 days
Default screening record
- by oral route 2 times per day per package directions
- by oral route 2 times per day per package directions for 5 days
- 3 tablets by oral route 2 times per day in the morning and evening per package directions
- 3 tablets by oral route 2 times per day in the morning and evening for 5 days per package directions
- 2 tablets by oral route 2 times per day in the morning and evening for 5 days per package directions
- 2 tablets by oral route 2 times per day in the morning and evening per package directions
- None
Contraindicated
- None
Severe
Moderate
- None
- None
Contraindicated
- None
Severe
Moderate
- None
PAXLOVID (nirmatrelvir/ritonavir)
- COVID-19
- None
- None
More Frequent
Severe
Less Severe
- None
- None
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- None
Less Severe
- None
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
None
Nirmatrelvir-ritonavir
- Severity Level:
2
- Additional Notes: Insufficient human data available on developmental toxicity risk
Contraindicated
None
General | Excretion Potential | Effect on Infant | Notes |
None |
Precaution Exists
None
General | Excretion Potential | Effect on Infant | Notes |
None |
No Known Risk
None
General | Excretion Potential | Effect on Infant | Notes |
None |
Contraindicated
None
Precaution Exists
Nirmatrelvir/ritonavir
Renal-dose adjustment required in patients with moderate renal impairment (eGFR 30-59mL/min). Not recommended for use in patients with severe renal impairment (eGFR <29mL/min).
Organ / System | HEP | REN | CARD | ENDO | NEURO / PSYCH | PULM |
Increased Risk / Adverse Effects | Y | N | N | N | N | N |
BEERS: N HEDIS: N STOPP: N
No Known Risk
None
- None
COVId-19 | |
J12.82 | Pneumonia due to coronavirus disease 2019 |
U07.1 | COVId-19 |
0-9 | A-Z |
---|---|
J12.82 | Pneumonia due to coronavirus disease 2019 |
U07.1 | COVId-19 |